Show simple item record

dc.contributor.authorEbenhan, Thomas
dc.contributor.authorZeevaart, Jan Rijn
dc.contributor.authorKleynhans, Janke
dc.contributor.authorJeong, Jae Min
dc.contributor.authorSathekge, Mike
dc.date.accessioned2020-10-13T11:25:55Z
dc.date.available2020-10-13T11:25:55Z
dc.date.issued2020
dc.identifier.citationEbenhan, T. et al. 2020. Non-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agents. European journal of nuclear medicine and molecular imaging, (In press). [https://doi.org/10.1007/s00259-020-04975-9]en_US
dc.identifier.issn1619-7070
dc.identifier.issn1619-7089 (Online)
dc.identifier.urihttp://hdl.handle.net/10394/35953
dc.identifier.urihttps://link.springer.com/article/10.1007/s00259-020-04975-9
dc.identifier.urihttps://doi.org/10.1007/s00259-020-04975-9
dc.description.abstractIntroduction Non-invasive imaging techniques (especially single-photon emission tomography and positron emission tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. Methods and Scope This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-photon emission tomography and positron emission tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Conclusion Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausibleen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.subjectArginyl-glycyl-aspartic aciden_US
dc.subjectIntegrin αVβ1en_US
dc.subjectIntegrin αVβ3en_US
dc.subjectPositron emission tomographyen_US
dc.subjectSingle-photon computed tomographyen_US
dc.subjectOptical imagingen_US
dc.subjectRGDen_US
dc.titleNon-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agentsen_US
dc.typeArticleen_US
dc.contributor.researchID16951484 - Zeevaart, Jan Rijn


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record